knowledge -WSS

knowledge

author：entertainment 2025-10-02 09:47:33 - browse：84

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Problems with a popular proposal to regulate AI in health care

WSS

Readout LOUD: Venture capital, Gilead, and more M&A

Antibiotic resistance and the global rise in human conflict

The Biogen Aduhelm mess could happen again

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Problems with a popular proposal to regulate AI in health care

hotspot

knowledge

explore

Guidelines to prevent youth baseball injuries need more muscle

Chronically ill young patients struggle to find fertility info

Medicare details structure of new drug price negotiation program

Federal weight loss drug coverage is 30 years out of date

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

New weight loss drugs work. But how can they best be used?

New air purifier tech could be key to improving indoor air quality

Why Novartis is going to walk from its acquisition of MorphoSys

As demand for Covid shots wanes, Moderna seeks its next success

Readout LOUD: Venture capital, Gilead, and more M&A

knowledge

Updated Covid vaccine has 54% effectiveness, new study suggests

Burning questions for the 2024 JPM Healthcare Conference

Goldman Sachs launches $650M fund for life science investments

U.K. sequencing study surfaces new findings about tumor DNA

Global cancer cases to surge 77% by 2050, WHO report says

Padmanee Sharma of MD Anderson at center of lawsuit over credit

entertainment

focus

knowledge

explore